AbbVie Inc. $ABBV Shares Purchased by Mission Wealth Management LP

Mission Wealth Management LP raised its position in shares of AbbVie Inc. (NYSE:ABBV) by 119.1% in the second quarter, HoldingsChannel.com reports. The firm owned 69,052 shares of the company’s stock after buying an additional 37,531 shares during the period. Mission Wealth Management LP’s holdings in AbbVie were worth $17,376,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the company. Litman Gregory Wealth Management LLC acquired a new stake in shares of AbbVie in the fourth quarter valued at $28,000. Imprint Wealth LLC grew its holdings in AbbVie by 56.2% during the fourth quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock worth $29,000 after acquiring an additional 45 shares during the period. Legacy Wealth Managment LLC ID grew its holdings in AbbVie by 115.9% during the fourth quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company’s stock worth $31,000 after acquiring an additional 73 shares during the period. IFC & Insurance Marketing Inc. bought a new stake in AbbVie in the fourth quarter worth about $31,000. Finally, WestEnd Advisors LLC raised its position in AbbVie by 160.4% in the fourth quarter. WestEnd Advisors LLC now owns 138 shares of the company’s stock worth $32,000 after acquiring an additional 85 shares in the last quarter. 70.23% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on ABBV. DZ Bank raised shares of AbbVie from a “hold” rating to a “strong-buy” rating in a report on Thursday, April 30th. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of AbbVie in a research note on Tuesday, June 23rd. Citigroup increased their target price on shares of AbbVie from $230.00 to $260.00 and gave the company a “neutral” rating in a research note on Wednesday, July 15th. Erste Group Bank upgraded shares of AbbVie from a “hold” rating to a “buy” rating in a report on Wednesday, August 5th. Finally, Canaccord Genuity Group lifted their price target on shares of AbbVie from $282.00 to $290.00 and gave the stock a “buy” rating in a research report on Monday, August 3rd. Two analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat, AbbVie presently has an average rating of “Moderate Buy” and an average price target of $274.33.

AbbVie Stock Performance

Shares of NYSE:ABBV opened at $249.12 on Thursday. The firm has a 50 day simple moving average of $243.99 and a 200 day simple moving average of $225.73. AbbVie Inc. has a 52 week low of $190.75 and a 52 week high of $267.47. The company has a market cap of $440.14 billion, a PE ratio of 70.37, a price-to-earnings-growth ratio of 0.83 and a beta of 0.30.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, topping the consensus estimate of $3.61 by $0.04. The firm had revenue of $16.99 billion for the quarter, compared to analysts’ expectations of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The company’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same period in the previous year, the company posted $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, equities analysts predict that AbbVie Inc. will post 14.07 earnings per share for the current year.

AbbVie Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, August 14th. Investors of record on Wednesday, July 15th will be given a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 2.8%. The ex-dividend date of this dividend is Wednesday, July 15th. AbbVie’s payout ratio is presently 195.48%.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Canada supports UBRELVY reimbursement: Canada’s Drug Agency recommended reimbursement of UBRELVY for acute migraine treatment in adults. The decision could improve access and provide another growth opportunity for AbbVie’s neuroscience portfolio. AbbVie Wins Canada Reimbursement Backing for Adult Migraine Treatment
• Positive Sentiment: BOTOX regulatory progress: AbbVie’s BOTOX filing helped attract investor attention, adding potential support for the aesthetics business and contributing to the stock’s recent strength. AbbVie Gains on Botox Filing
• Positive Sentiment: Immunology remains the key growth engine: Skyrizi and Rinvoq delivered strong sales, market-share gains and contributions from new indications, helping drive AbbVie’s second-quarter growth. Recent results also exceeded consensus estimates for earnings and revenue. How Much Did Immunology Drugs Contribute to AbbVie’s Q2 Performance?
• Neutral Sentiment: Pipeline updates provide optionality but limited immediate impact: AbbVie completed early testing of a venetoclax combination in high-risk myelodysplastic syndromes and completed a Phase 3 BOTOX jawline study. The updates advance development, but the reports did not provide definitive clinical results. AbbVie’s Venetoclax Combo in High-Risk MDS
• Neutral Sentiment: Analyst target increase reflects limited near-term upside: BNP Paribas Exane raised its price target from $218 to $247 while retaining a neutral rating, implying the shares were slightly above its revised valuation. Erste Group also modestly reduced its FY2027 EPS forecast but kept a Buy rating. BNP Paribas Exane AbbVie Price Target
• Negative Sentiment: Apogee acquisition increases leverage: Shareholders approved AbbVie’s Apogee Therapeutics acquisition, expanding the pipeline but requiring roughly $8 billion of additional debt. Investors focused on dividend safety may view the higher leverage and execution risk negatively. AbbVie Piles on $8 Billion in Debt for Its Apogee Deal

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.